Interferon alpha-D ; IFN-alpha-1/13 ; LeIF D ; IFNA13
Antigen
IFNA1
Description
All known subtypes of IFN- alpha show the same antiviral antiparasitic, antiproliferative activities. IFN-alpha forms are produced by monocytes/macrophages, lymphoblastoid cells, fibroblasts, and a number of different cell types following induction by viruses, nucleic acids, glucocorticoid hormones, and low-molecular weight substances. All IFN-alpha subtypes possess a common conserved sequence region between amino acid positions 115-151 while the amino-terminal ends are variable. Many IFN-alpha subtypes differ in their sequences at only one or two positions. IFN-alpha and IFN-beta are thought to bind to the same receptor. Signal transduction mechanisms elicited after binding of IFN-alpha to its receptors involves tyrosine phosphorylation of various non-receptor tyrosine kinases belonging to the Janus kinases.
Field Of Use
Research Use Only.
Not for human or animal therapeutic or diagnostic use.
Quantity
20 µg
Regulatory
RUO
Source
E. coli
Host
Human
Endotoxin Level
<1.0 EU/μg of recombinant protein as determined by the LAL method
Weight
19.7 kDa
Format
Lyophilized PowderLyophilized from a 0.2 μm filtered solution in Tris and NaCl (pH 8.0)
Purity
>95% as determined by SDS-PAGE
Storage
The lyophilized protein is stable for at least one year from date of receipt at -70°C. Upon reconstitution, this cytokine can be stored in working aliquots at 2° - 8°C for one month, or at -20°C for six months, with a carrier protein without detectable loss of activity.